Sebetralstat clinical trials
Also written KVD900.
How each study uses sebetralstat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sebetralstat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 3 Jul 2025 · EKTERLY · NDA 219301 (FDA, Drugs@FDA)
- European Union
- 17 Sept 2025 · Ekterly · EMEA/H/C/006211 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2022 | 3 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test sebetralstat.
- Nov 2027Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)Phase 4 · KalVista Pharmaceuticals, Ltd.
Studies
Open first, then newest update. How each study uses sebetralstat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)RecruitingPhase 4KalVista Pharmaceuticals, Ltd.NCT07654829Written as KVD900 600 mg
- Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or IICompletedPhase 3KalVista Pharmaceuticals, Ltd.NCT06467084Written as KVD900 150 mg
- PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 TrialCompletedPhase 3KalVista Pharmaceuticals, Ltd.NCT05511922Written as KVD900 600 mg
- An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)CompletedPhase 3KalVista Pharmaceuticals, Ltd.NCT05505916Written as KVD900 600 mg
- A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or IICompletedPhase 2KalVista Pharmaceuticals, Ltd.NCT04208412Written as KVD900
- A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)CompletedPhase 3KalVista Pharmaceuticals, Ltd.NCT05259917Written as KVD900 600 mg
- A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy VolunteersCompletedPhase 1KalVista Pharmaceuticals, Ltd.NCT04349800Written as KVD900
Codes
What other systems call sebetralstat · ClinicalTrials.gg INT001998
- MeSH (NLM) C000726128sebetralstatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) O5ZD2TU2B7SEBETRALSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q131152152sebetralstatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C184930SebetralstatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000726128 | sebetralstat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | O5ZD2TU2B7 | SEBETRALSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q131152152 | sebetralstat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C184930 | Sebetralstat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.